May. 12 at 8:20 PM
$IMNM Immunome reports Q1 EPS (52c), consensus (57c)
As of March 31, 2025, cash, cash equivalents and marketable securities totaled
$317.3 million. This total includes net proceeds of
$161.7 million from the January 2025 financing and reflects approximately
$11 million in payments during the quarter related to non-recurring IM-1021 milestones and 2024 annual performance bonuses. Immunome expects its current cash position to fund operations into 2027. "Immunome continued to build momentum in the first quarter of 2025," said Clay B. Siegall, CEO.
"We remain on track to share topline data for the RINGSIDE trial of varegacestat in the second half of 2025, and we are optimistic that varegacestat will demonstrate differentiated efficacy across multiple endpoints. Varegacestat is complemented by a robust pipeline of differentiated programs with first-in-class or best-in-class potential. The dose escalation portion of the Phase 1 clinical trial of IM-1021, our ROR1 ADC, is ongoing in solid tumors and lymphoma.
Following the recent clearance of the IND for IM-3050, our FAP radiotherapy, we expect to start a clinical trial for that program in the second half of this year. We are making progress on IND-enabling manufacturing for IM-1617, IM-1335 and IM-1340, each of which incorporate our differentiated TOP1 inhibitor, HC74."
